- Use of off-label drugs in cancer care again under review
Springfield Clinic, Springfield, IL, USA
ONS News 20:8. 2005
- Investigational therapies for metastatic thyroid carcinoma
R Michael Tuttle
Joan and Sanford I Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Natl Compr Canc Netw 5:641-6. 2007
..Given the dramatic increase in availability of thyroid cancer clinical trials, all patients with radioactive iodine-refractory, progressive metastatic thyroid cancer should be considered for inclusion in a novel therapy trial...
- Ethical framework for the use of sham procedures in clinical trials
Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892 1156, USA
Crit Care Med 31:S126-30. 2003
- Rethinking research ethics
Mount Sinai School of Medicine
Am J Bioeth 5:7-28. 2005
..These include: the primacy of informed consent, the protection of the vulnerable, the substitution of beneficence for research's social purpose, and the introduction of an untenable distinction between innovation and research...
- Research versus innovation: real differences
University of Tennessee Health Science Center, USA
Am J Bioeth 5:42-3; author reply W15-8. 2005
- Ethical issues in fetal surgery research
Frank A Chervenak
Department of Obstetrics and Eynecology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, J 130, New York, NY 10021, USA
Best Pract Res Clin Anaesthesiol 18:221-30. 2004
..We demonstrate the applicability of this framework to fetal surgery research for spina bifida, a common fetal anomaly...
- Third-party payers and the cost of biomedical research
Ana S Iltis
Center for Health Care Ethics, Saint Louis University, St Louis, MO, USA
Kennedy Inst Ethics J 15:135-60. 2005
- Congressmen say military should have the right to informed consent
Dennis M Maloney
The Deem Corporation, P O Box 44069, Omaha, NE 68144, USA
Hum Res Rep 20:9. 2005
- Ethics of innovative surgery: US surgeons' definitions, knowledge, and attitudes
Angelique M Reitsma
Center for Biomedical Ethics, University of Virginia, PO Box 800758, Charlottesville, VA 22908 0758, USA
J Am Coll Surg 200:103-10. 2005
..Surgeons were also invited to self-report knowledge about current federal regulations guiding human subject research and rules for informed consent for and IRB review of clinical research...
- When is surgery research? Towards an operational definition of human research
C E Margo
Watson Clinic, Lakeland, Florida, USA
J Med Ethics 27:40-3. 2001
..Enforcing more rigid and less ambiguous guidelines of human research may curtail enrolment into some studies, but it will also protect patients from being used as subjects without their knowledge...
- Innovation to research: some transitional obstacles in critical care units
Cynthiane J Morgenweck
Center for the Study of Bioethics, Medical College of Wisconsin, Milwaukee 53226, USA
Crit Care Med 31:S172-7. 2003
- Beyond informed consent: the therapeutic misconception and trust
I de Melo-Martin
Division of Medical Ethics, Department of Public Health, Weill Cornell Medical College, 411 E 69th Street, New York, NY, USA
J Med Ethics 34:202-5. 2008
..We show that concerns about misplaced trust and exploitation of such trust are also relevant, and ought to be taken into account, when considering why the therapeutic misconception matters ethically...
- [Some recent ethical dilemmas in randomized controlled clinical trials]
Semmelweis Egyetem Magatartástudományi Intézet, Bioetika Részleg, Budapest, Nagyvárad tér 4 1089
Orv Hetil 149:1753-60. 2008
..method" in the Declaration of Helsinki 2000. The article makes an attempt to survey some of the lessons of these debates...
- Bioterrorism, biodefense, and biotechnology in the military: a comparative analysis of legal and ethical issues in the research, development, and use of biotechnological products on American and British soldiers
Ashley R Melson
The Berkeley Law Firm, PC, USA
Albany Law J Sci Technol 14:E1-E44. 2004
- Is it time to rethink the expanded-access programs for HIV infection?
University of Pennsylvania, Philadelphia, PA 19104, USA
J Infect Dis 196:974-7. 2007
- Trauma nursing
Directorate of Combat and Doctrine Development, USA
J Trauma 62:S77. 2007
- Investigational test protocols must include informed consent
MLO Med Lab Obs 36:32. 2004
- Smallpox revisited?
Michael J Selgelid
University of the Witwatersrand, South Africa
Am J Bioeth 3:W-IF 1. 2003
..e. secret). I conclude by recommending numerous future areas for ethics research related to the weaponization of smallpox...
- A traditional jewish approach to risky medical treatment
Department of Radiology, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA
Cancer Invest 25:209-15. 2007
..The approach of Jewish law is valuable in formulating a generic approach to the area of risky medical treatments and is beneficial in understanding the choices that Jewish patients might make regarding their care...
- Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity
Kedar N Prasad
Center for Vitamin and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, Denver 80262 0278, USA
Integr Cancer Ther 3:310-22. 2004
..This review also discusses the reasons for the current debates regarding the use of antioxidants during radiation or chemotherapy...
- Factors affecting innovation in pediatric surgery: hospital type and appendectomies
Deena J Chisolm
Department of Pediatrics, The Ohio State University, College of Medicine and Columbus Children s Research Institute, Columbus, OH 43205, USA
J Pediatr Surg 41:1809-13. 2006
..This study examines the patterns of LA using a national database, focusing on variations in care between children's and general hospitals...
- Top 10 health-care trends for 2003: rising demand, increasing revenues and innovative technologies
Russell C Coile
Russ Coiles Health Trends 15:1, 3-10. 2003
- The value of antihypertensive drugs: a perspective on medical innovation
David M Cutler
Department of Economics, Harvard University, Cambridge, Massachusetts, USA
Health Aff (Millwood) 26:97-110. 2007
..More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents...
- Access for the terminally ill to experimental medical innovations: a three-pronged threat
University of Pennsylvania, USA
Am J Bioeth 7:3-6. 2007
- Difficulties in performing clinical trials of antithrombotic therapy in neonates and children
M Patricia Massicotte
Paediatric Thrombosis, Stollery Children s Hospital, University of Alberta, Edmonton, Alberta, Canada
Thromb Res 118:153-63. 2006
..Means for overcoming these challenges are also addressed...
- Research-related injury: problems and solutions
Larry D Scott
University of Texas Medical School at Houston, USA
J Law Med Ethics 31:419-28. 2003
- The scientific establishment of a new therapeutic intervention for developmental conditions: practical and ethical principles
Institute for EGT, Nagahama Shinryojyo, 8 3 Nagahama, Shimokoshiki mura, Satsuma gun, 896 1411 Kagoshima, Japan
Childs Nerv Syst 19:711-5. 2003
- Testing and estimation in flexible group sequential designs with adaptive treatment selection
Section of Medical Statistics, Core Unit for Medical Statistics and Informatics, Medical University of Vienna, Spitalgasse 23, A 1090 Wien, Austria
Stat Med 24:3697-714. 2005
..Also point estimation in adaptive trials is considered. The methodology is illustrated in a detailed example based on an actual planned study...
- An innovative approach to the care of patients on phase I and phase II clinical trials: the role of the experimental therapeutics nurse
The Children s Hospital of Philadelphia, USA
J Pediatr Oncol Nurs 22:353-64. 2005
..The broader role of nursing in clinical trials, the multidisciplinary challenges of experimental therapies, and the development of an innovative approach to caring for patients on phase I/II studies are discussed...
- Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?
Ralph W Moss
Cancer Communications, Lemont, Pennsylvania 16851, USA
Integr Cancer Ther 5:63-82. 2006
..A blanket rejection of the concurrent use of antioxidants with chemotherapy is not justified by the preponderance of evidence at this time and serves neither the scientific community nor cancer patients...
- New investigational therapies for gastroesophageal reflux disease
Joel E Richter
Department of Medicine, Temple University School of Medicine, 3401 North Broad Street, 8th Floor, Parkinson Pavilion, Philadelphia, PA, 19140, USA
Thorac Surg Clin 15:377-84. 2005
..Which of these drugs, if any, will be the new GERD drug for the millennium is unknown. There is no question, however, that improved drug treatments will parallel a better understanding of the complicated pathophysiology of GERD...
- The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials
Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
Account Res 10:301-15. 2003
..We argue that an adequate control intervention can be selected if people designing a trial explicitly take into consideration the ethical principle of equipoise, also known as "the uncertainty principle."..
- Compassionate approval process for experimental gene-based products
J Clin Oncol 26:1899-900. 2008
- Advances in the treatment of breast cancer
Department of Breast Medical Oncology and Phase I Program, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Pharmacol Ther 83:26-36. 2008
- Ophtec iris reconstruction lens United States clinical trial phase I
Marianne O Price
Cornea Research Foundation of America, Indianapolis, Indiana, USA
Ophthalmology 111:1847-52. 2004
..To determine the safety and efficacy of the Ophtec model 311 iris reconstruction lens for treatment of visual disturbances, such as glare or photophobia, related to partial or total absence of the human iris...
- [Traditional and translational medicine]
Laboratoire de Pharmacologie, Universite Catholique de Louvain, Avenue Hippocrate 54, UCL 5410 B1200 Bruxelles
Bull Acad Natl Med 191:715-25; discussion 725-6. 2007
..The European program entitled 'The Innovative Medicines Initiative' could facilitate the translation of information from benchtop to bedside...
- FDA perspective on antivirals against biothreats: communicate early and often
US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Counter Terrorism and Emergency Coordination, 10903 New Hampshire Avenue, White Oak Campus, Silver Spring, MD 20993, United States
Antiviral Res 78:60-3. 2008
..Efficient development of therapeutics against these agents requires collaborative efforts among industry, academia and federal agencies...
- Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors
Michael D Jensen
Endocrine Research Unit, Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Obesity (Silver Spring) 14:143S-149S. 2006
..g., acipimox, pioglitazone). Surgically implanted gastric pacemaker systems that modulate vagus nerve activity and delay gastric emptying are under study...
- [Limitations of pharmacoeconomics from a clinical-pharmacological point of view]
Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Osterreich
Wien Med Wochenschr 156:619-21. 2006
..Moreover situations with (5) incremental, small benefit, (6) lack of precedents in case of innovations or (7) obvious "efficacy-effectiveness gaps" may pose challenges in the pricing decision process for pharmaceuticals...
- The risk-benefit balance in the United States: who decides?
Frederick S Pardee RAND Graduate School, Santa Monica, California, USA
Health Aff (Millwood) 26:625-35. 2007
..Our ultimate purpose is to urge the U.S. health policy community to develop a more consistent way of thinking about how risk-benefit decisions could be guided by general principles...
- The arthroscopic surgeon: cowboy and scientist. Presidential address
Stephen S Burkhart
Arthroscopy 19:678-83. 2003
- Medical self-defense, prohibited experimental therapies, and payment for organs
UCLA School of Law, USA
Harv Law Rev 120:1813-46. 2007
- Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001
R Phillip Dellinger
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08854, USA
J Crit Care 21:38-47. 2006
..Once a therapy is approved, adopting less stringent but still appropriate criteria for the use of that therapy in clinical practice may be appropriate...
- The thin line between malpractice and benefit determination
Jack A Rovner
Manag Care 12:31-2. 2003
Michael P Aronson
Department of Obstetrics and Gynecology, University of Massachusetts Medical School, Worcester 01605 2982, USA
Am J Obstet Gynecol 192:1483-7. 2005
- Current drug development portfolio for antimalarial therapies
Giancarlo A Biagini
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
Curr Opin Pharmacol 5:473-8. 2005
..The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline...
- Access to clinical devices through nontraditional routes
Robert J Klepinski
Fredrikson and Byron, P A, Minneapolis, MN, USA
Food Drug Law J 62:849-63. 2007
- Listen to all the voices: an advocate's perspective on early access to investigational therapies
Clin Trials 3:149-53. 2006
..The essay that follows is inspired by the need for other voices from the patient and advocacy communities to be heard in this debate...
- Can we afford innovation?
Cedars Sinai Medical Center, Los Angeles, California 90048, USA morgenstern cshs org
Surg Innov 14:138-9. 2007
- Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials
Amgen Inc, One Amgen Center Drive, 24 2 C, Thousand Oaks, CA 91320, USA
Stat Med 27:382-91. 2008
- Don't avoid experimental treatments
Eric E Shore
Med Econ 84:30. 2007
- Therapeutic developments in peroxisome biogenesis disorders
M C McGuinness
Kennedy Krieger Institute, Room 400A, 707 North Broadway, Baltimore, MD 21205, USA
Expert Opin Investig Drugs 9:1985-92. 2000
..Dietary supplementation and/or modification and pharmacological induction of peroxisomes as treatment strategies for PBD patients will be the subject of this review...
- Cisplatin overdose: toxicities and management
Roger Y Tsang
Department of Oncology, Division of Medical Oncology, Cross Cancer Institute and University of Alberta, Alberta, Canada
Drug Saf 32:1109-22. 2009
- Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments
Robert A Nathan
University of Colorado Health Sciences Center, Denver, Colorado, USA
Ann Allergy Asthma Immunol 90:182-90; quiz 190-1, 232. 2003
To review the mechanisms and clinical efficacy of leukotriene receptor antagonists, which are investigational therapies for allergic rhinitis, compared with intranasal corticosteroids and nonsedating antihistamines, which are the most ..
- Experimental therapies in renal replacement: the effect of two different potassium acetate-free biofiltration protocols on striated muscle fibers
Department of Internal Medicine, University of Messina, Messina, Italy
Ther Apher Dial 11:375-81. 2007
..AFB(K) can minimize the negative effects of standard AFB treatment on neuromuscular excitability, most likely through a more gentle variation of potassium levels during dialysis...
- The pathogenesis and treatment of pruritus and fatigue in patients with PBC
E A Jones
Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The Netherlands
Eur J Gastroenterol Hepatol 11:623-31. 1999
- A biological global positioning system: considerations for tracking stem cell behaviors in the whole body
Shengwen Calvin Li
Center for Neuroscience and Stem Cell Research, Children s Hospital of Orange County Research Institute, University of California Irvine, 455 South Main Street, Orange, CA 92868, USA
Stem Cell Rev 6:317-33. 2010
..We then discuss an ideal procedure for labeling and tracking stem cells in vivo, finally, we present a novel imaging system based on our experiments...
- Outcome predictors in substance use disorders
Domenic A Ciraulo
Division of Psychiatry, Boston University School of Medicine, Doctor s Office Building, 720 Harrison Avenue, Suite 914, Boston, MA 02118, USA
Psychiatr Clin North Am 26:381-409. 2003
..As the ability to subtype disorders based on meaningful biologic differences grows, it is anticipated that several relevant outcome predictors that are specific for pharmacotherapy will emerge...
- The millennium criteria for the diagnosis of atopic dermatitis
J D Bos
Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands
Exp Dermatol 7:132-8. 1998
..For study purposes, we suggest that the mandatory and principal criteria are sufficient. They are now evaluated and validated in ongoing atopic dermatitis treatment studies...
- Final common pathway for tinnitus: theoretical and clinical implications of neuroanatomical substrates
Martha Entenmann Tinnitus Research Center, Forest Hills, New York, USA
Int Tinnitus J 15:5-50. 2009
- Induction therapy in pediatric renal transplant recipients: an overview
Department of Nephrology, Children s National Medical Center, Washington, District of Columbia 20010, USA
Paediatr Drugs 9:323-41. 2007
..Newer lymphocyte-depleting agents such as alemtuzumab may be better utilized in minimization regimens involving one or two oral maintenance immunosuppressive agents...
- Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model
Jin A Lee
Departments of Pediatrics, Seoul National University Boramae Hospital and Seoul National University College of Medicine, Seoul, South Korea
Pediatr Res 67:42-6. 2010
..Neurologic performance was significantly impaired only on the cylinder test after HI (p = 0.034), and MSC transplants improved it (p = 0.010). These suggest MSC can be a candidate for the treatment of neonatal HIE...
- A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings
Department of Pathology, The Edward A Doisy Department of Biochemistry and Molecular Biology, St Louis University School of Medicine, Missouri 63104, USA
Pediatr Res 49:342-8. 2001
..This feature makes them extremely useful for testing intrauterine therapies...
- Cancer-induced cachexia: a guide for the oncologist
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA
J Soc Integr Oncol 7:155-69. 2009
..Experimental therapies are also discussed, including nonsteroidal antiinflammatory drugs, tumor necrosis factor alpha antagonists, tetrahydrocannabinol, growth hormone, ghrelin, oxandrolone, and omega-3 fatty acids...
- Hyperoxaluria and systemic oxalosis: current therapy and future directions
Amy E Bobrowski
Feinberg School of Medicine, Northwestern University, Division of Kidney Diseases, Department of Pediatrics, Children s Memorial Hospital, 2300 Children s Plaza 37, Chicago, IL 60614, USA
Expert Opin Pharmacother 7:1887-96. 2006
..Such approaches give hope for a future therapeutic cure for primary hyperoxaluria that includes correction of the underlying genetic defect without exposure to the life-long dangers associated with organ transplantation...
- The twitcher mouse: a model for Krabbe disease and for experimental therapies
Department of Neurology, University of North Carolina School of Medicine, Chapel Hill 27599, USA
Brain Pathol 5:249-58. 1995
..It is expected that this model will be useful for basic studies on treatment of this group of genetic disorders affecting the brain through transgenic and/or gene therapy approaches...
- New innovative therapies for benign prostatic hyperplasia: any advance?
H Christoph Klingler
Department of Urology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Curr Opin Urol 13:11-5. 2003
..Not surprisingly, interest centres on either understanding of prostatic growth during ageing or on various medical or interventional treatments...
- Cellular and molecular basis of portal hypertension
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
Clin Liver Dis 5:629-44. 2001
- Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible
Division of Gastroenterology, McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, 1201 Broad Rock Rd, Richmond, VA 23249, USA
Postgrad Med 109:52-4, 57-60, 63-5 passim. 2001
..However, future research will likely focus on the correction of alterations in neurotransmission. It is hoped that newer therapies will provide protection from the putative neurotoxins that cause secondary defects in neurotransmission...
- Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting
S Maria Hospital, Terni, Italy
Ann Oncol 20:1867-73. 2009
..The aim of the study was to detect a dose response...
- Placebo treatment in acute stroke trials : benefit or harm to patients?
Departments of Neurology, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
Stroke 31:355-7. 2000
..We sought to determine the effect on outcome of participating in a clinical stroke trial while being treated with placebo...
- Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility
Brain Repair Group, School of Biosciences, Cardiff University, Cardiff CF10 3US, UK
Behav Brain Res 165:181-6. 2005
- Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase
Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
Hum Mol Genet 12:961-73. 2003
..Corrective gene therapy in this model should provide high enough levels of expression of normal GUS monomers to overcome the dominant negative effect of mutant monomers on newly synthesized GUS tetramers in most tissues...
- Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine
Christian de Mey
ACPS Applied Clinical Pharmacology Services, Mainz Kastel, Germany
Arzneimittelforschung 56:205-11. 2006
..232) and 1.07 (90% CI: 0.95 to 1.20 - CVm: 0.220). In view of important medical-ethical constraints not to expose an unreasonably high number of subjects, these findings could be accepted as a sufficient demonstration of bioequivalence...
- Chronic pruritus: targets, mechanisms and future therapies
Department of Anesthesiology and Intensive Care, Competence Center for the Diagnostic and Therapy of Chronic Pruritus, University of Munster, Munster, Germany
Drug News Perspect 21:541-51. 2008
..The present review aims to provide an overview of current neurophysiological and neurochemical therapeutic models in chronic pruritus...
- Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group
Department of Internal Medicine Hematooncology, University Hospital Brno, Czech Republic
Onkologie 27:275-9. 2004
..High-dose chemotherapy followed by autologous stem cell transplantation (AT) is accepted as first-line therapy for patients with multiple myeloma (MM), with very good tolerance and low mortality (2-3%)...
- An orthotopic skull base model of malignant meningioma
Gilson S Baia
Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
Brain Pathol 18:172-9. 2008
..Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents...
- Hydroalcoholic human placental extract: skin pigmenting activity and gross chemical composition
Department of Cellular Biochemistry, Indian Institute of Chemical Biology, Calcutta
Int J Dermatol 34:61-6. 1995
..A hydroalcoholic human placental extract has been developed by us with pigmenting activity based on experimental therapies. Its chemical analysis was the primary objective of this study...
- Sickle cell anemia in the female patient
Department of Obstetrics and Gynecology, University of Miami Jackson Memorial Hospital, Miami, Florida, USA
Obstet Gynecol Surv 61:343-52. 2006
..Whether any of these new agents are safe in pregnancy has yet to be determined...
- Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments
R M Greenblatt
Department of Medicine, University of California, School of Medicine, San Francisco
J Acquir Immune Defic Syndr 4:136-43. 1991
..Despite having decided to obtain care at a university-based clinic, many of the participants of this study also chose to receive unorthodox therapies and care from nonprimary medical providers.(ABSTRACT TRUNCATED AT 250 WORDS)..
- Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients
Wilhelm H Schmitt
Fifth Department of Medicine, University Hospital Mannheim of the University of Heidelberg, Mannheim, Germany
Kidney Int 65:1440-8. 2004
..Anecdotal data suggest that antithymocyte globulin (ATG) may be a treatment option for these patients. We now describe 15 patients treated with ATG for refractory Wegener's granulomatosis...
- Investigational therapies in the treatment of obesity
Marcio C Mancini
Sao Paulo University, Obesity and Metabolic Syndrome Group of the Endocrinology and Metabology Service, Faculty of Medicine, Hospital das Clinicas, Sao Paulo, Brazil
Expert Opin Investig Drugs 15:897-915. 2006
..These differing approaches are reviewed and commented on in this article...
- Generalized interstitial granuloma annulare--response to adalimumab
Department of Dermatology, University of Heidelberg, Heidelberg, Germany
Int J Dermatol 49:457-60. 2010
..A foreign-body granuloma formation induced by an unknown inciting antigen is suspected. Generalized forms often coincides with recalcitrant progression and frustrated experimental therapies...
- Novel therapies for pemphigus vulgaris: an overview
Oliver A Perez
Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
Drugs Aging 26:833-46. 2009
..This review highlights the latest case reports and studies that employ established as well as new therapeutics in a novel way to treat this rare, but serious, disorder...
- Reference drug programs: effectiveness and policy implications
Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
Health Policy 81:17-28. 2007
..This paper summarizes the mechanism and rationale of RDPs, presents evidence of their economic effectiveness and clinical safety, and concludes with some practical implications of implementing RDP policies...
- Acute respiratory distress syndrome
Michael P Mortelliti
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
Am Fam Physician 65:1823-30. 2002
..Many patients who survive ARDS have permanent, mild to moderate impairment of lung function. Quality of life after hospitalization with ARDS may be poorer than that in similar patients without ARDS...
- Inhibition of coxsackievirus B3 and related enteroviruses by antiviral short interfering RNA pools produced using phi6 RNA-dependent RNA polymerase
Department of Virology, University of Turku, Kiinamyllynkatu 13, FIN 20520 Turku, Finland
J Gen Virol 90:2468-73. 2009
..The phi6-siRNA pool also inhibited replication of other enterovirus B species, such as coxsackievirus B4 and coxsackievirus A9...
- Androgen receptors in prostate cancer
Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
Endocr Relat Cancer 9:155-70. 2002
..New experimental therapies for prostate cancer are aimed to down-regulate AR expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens...
- Clinical implications of chromosomal abnormalities in multiple myeloma
Department of Hematology, 251 General Airforce Hospital, Athens, Greece
Leuk Lymphoma 47:803-14. 2006
..melphalan and autologous stem cell transplantation (ASCT), and should therefore be treated with more investigational therapies. Alternatively, eligible patients who do not have these poor risk factors are more likely to benefit ..
- The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
Jeffrey J Olson
Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
J Neurooncol 96:115-42. 2010
What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors?
- Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models
1st Department of Pathology and Experimental Cancer Research, Semmelweis University Medical School, Budapest, Hungary
Diabetes Obes Metab 12:393-402. 2010
..Our novel peptidomimetic was tested for efficacy and lack of resistance induction in rodent models of obesity and appetite reduction...
- Experimental therapies in hypertrophic cardiomyopathy
Ali J Marian
Center for Cardiovascular Genetics, St Luke s Episcopal Hospital and Texas Heart Institute, Brown Foundation Institute of Molecular Medicine, The Unversity of Texas Health Science Center, Houston, TX 77030, USA
J Cardiovasc Transl Res 2:483-92. 2009
- When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events
Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
Can J Cardiol 14:24E-27E. 1998
..04). Results suggested that enoxaparin therapy compared with standard UFH therapy improves key clinical outcomes and saves money in patients with acute coronary syndrome...
- Survivin expression in tuberous sclerosis complex cells
Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry, University of Milan, Polo H San Paolo, Milano, Italy
Mol Med 13:166-77. 2007
..Future experimental therapies for TSC and LAM may result from the targeted inhibition of survivin, which may enhance sensitivity to TSC2 therapy...
- Hematopoietic engraftment of XLA bone marrow CD34(+) cells in NOG/SCID mice
Institut Paoli Calmettes, Centre de Thérapie Cellulaire et Génique, Marseille, France
Cytotherapy 11:198-205. 2009
- Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy
M A Lima
Department of Neurology, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, MA 02215, USA
J Neurol Neurosurg Psychiatry 81:1288-91. 2010
..In absence of a specific treatment, immunotherapies aiming at boosting the cellular immune response against JCV may improve the prognosis of PML...
- Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke
Department of Mathematics and Statistics, Medical and Pharmaceutical Statistics Research Unit, Lancaster University, Lancaster, UK
Stroke 40:1347-52. 2009
..We discuss the design and the appropriate sample size for phase II studies in stroke based on lesion volume...
- Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
Chi Mu Chuang
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Biomed Sci 16:49. 2009
..Antigen-specific immunotherapy has emerged as a novel alternate therapy for advanced stage cancers, which may be employed in conjunction with conventional therapies...
- A survey of case reports and case series of therapeutic interventions in the Archives of Dermatology
Department of Medicine and Division of Dermatology, John Stroger Hospital of Cook County, Chicago, Illinois 60612, USA
Int J Dermatol 48:592-7. 2009
..Case reports and case series are often the first line of clinical evidence in the medical literature and, until stronger evidence becomes available, are the only guidance to new therapies...
- Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target
Universite Paris Descartes, Paris, France
PLoS ONE 4:e7848. 2009
..In this study, we examined the role of GITR/GITRLigand interaction in the progression of autoimmune diabetes...
- Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy
I A Boere
Laboratory of Experimental Surgery and Oncology Ee102c, Erasmus Medical Center, Dr Molenwaterplein 50, 3016 GH Rotterdam, The Netherlands
Photochem Photobiol 78:271-7. 2003
..Non-responders did not show the rapid initial decay and had a significantly lower rate of photobleaching during the second phase of the decay (P = 0.012)...